Markers of normal and CSC are shared and this represents a drawback in development of cancer drugs directed against stem cells: as opposite, doublecortin like kinase 1 (Dclk1) is a specific CSC marker and does not mark normal stem cells[49]. Here, DCLK1 is linked to cancer.